ACBD3-AS1: ACBD3-AS1 is a long non-coding RNA (lncRNA) that has been studied in gastric cancer (GC) [PMC8325795]. In GC tumor samples, the expression of ACBD3-AS1 is higher, suggesting that it may function as an oncogene [PMC8325795]. ACBD3-AS1 expression does not differ significantly between different risk groups [PMC8325795]. However, it is lower in normal tissue compared to tumor tissue [PMC8325795]. ACBD3-AS1 is closely associated with several m6A lncRNAs in GC and its expression increases with the increased expression of these m6A lncRNAs in GC cells [PMC8325795]. Overexpression of ACBD3-AS1 has been shown to enhance cell viability and inhibit apoptosis by stimulating the expression of apoptosis-related genes [PMC8325795]. Additionally, ACBD3-AS1 has been found to interact with the JAK2 signaling pathway, suggesting its potential role as a tumor promoter in gastric carcinoma [PMC8325795]. ACBD3-AS1 is most positively correlated with AC092119.2, AC007038.1, AL139287.1, SNHG12, and C3orf35 [PMC8325795]. Its higher expression in cluster 2 indicates a potential harmful effect on the prognosis of gastric cancer patients [PMC8325795]. The overall survival rate of GC patients is highly related to the expression of ACBD3-AS1 [PMC8325795]. However, further studies are needed to fully understand the role of ACBD3-AS1 in GC cells and its potential as an oncogene [PMC8325795]. The differential expression analysis and correlation analysis further support the prognostic value of ACBD3-AS1 in GC patients. It was found that its higher expression was associated with the high-risk group in gastric cancer [PMC8325795]. In a different study, ACBD3-AS1 was identified as one of the top markers in cluster 8 of airway epithelium, indicating its potential role in lung-related analysis [PMC9889806]. Overall, ACBD3-AS1 is a lncRNA that shows differential expression in GC and is associated with various molecular pathways and potential prognostic markers [PMC8325795][PMC9889806].